Check patentability & draft patents in minutes with Patsnap Eureka AI!

Method for promoting production of SCFA by intestinal microbiota

A gut microbiology, gastrointestinal technology, applied in the treatment of Parkinson's disease, promoting the integrity of the intestinal barrier, and promoting the tolerogenic intestinal phenotype, can solve the problems of limited therapeutic effect and side effects.

Pending Publication Date: 2022-07-12
MULTIGERM UK ENTERPRISES
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current treatments for the disease have limited efficacy, and drug therapy is associated with significant side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for promoting production of SCFA by intestinal microbiota
  • Method for promoting production of SCFA by intestinal microbiota
  • Method for promoting production of SCFA by intestinal microbiota

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0210] The ability of probiotics in Symprove to affect three healthy human gut microbiomes was determined using an in vitro gut model (a human gut microbial ecosystem simulator equipped with mucosal compartments ); effects on bacterial diversity, SCFA production, and markers of inflammation were quantified following Symprove administration over three weeks. The manufacture of Symprove and its nutritional composition are further provided in WO 2006 / 035218, which is incorporated herein by reference.

[0211] 2. Materials and methods

[0212] 2.1. test

[0213] Symprove TM Obtained from Symprove Ltd and used as is. use system to experiment. Briefly, the system includes four reactor vessels (V). The first two reactors use the fill and draw principle to simulate the initial stages of food intake and digestion. Peristaltic pumps added food (140 mL, 3 times a day) and pancreatic juice / bile (60 mL, 3 times a day) to the stomach (V1) and small intestine (V2), respectively, an...

Embodiment 2

[0249] Further experiments were conducted to investigate the effect of Symprove on the gut microbiota of patients with severe cirrhosis or early-onset Parkinson's disease (PD). Experiments were also conducted on the gut microbiota of patients with inflammatory bowel disease (IBD), which is known to be treatable with Symprove.

[0250] The pathology of cirrhosis and PD is usually independent of the patient's gut bacterial flora. However, as shown in the data below, both PD and cirrhosis patients exhibit intestinal dysbiosis. Furthermore, different dysbiosis changes were observed between the two conditions. Thus, the presented data demonstrate the ability of Symprove to promote the rebalance of dysbiosis gut microbiota to a healthier state in various dysbiosis states and disease conditions.

[0251] 2. Materials and methods

[0252] Using bacterial inoculum of stool samples obtained from patients with PD, cirrhosis or IBD (3 donors per disease, run in parallel) using the meth...

Embodiment 3

[0350] Example 2 demonstrates that Parkinson's disease patients exhibit gastrointestinal dysbiosis because their gut microbiota differs from healthy donors. It has been speculated that dysbiosis of the gastrointestinal tract may contribute to the pathology of Parkinson's disease. Specifically, the disrupted microbiota may contribute to and / or be caused by inflammation, which itself can lead to increased gut permeability ('leaky gut'). Increased intestinal permeability may lead to increased expression and aggregation of misfolded alpha-synuclein, a protein aggregate characteristic of Parkinson's disease. Alpha-synuclein can then be transported to the brain via the vagus nerve, which is the conduit of the gut-brain axis. In addition, chronic intestinal inflammation secondary to altered gut microbiota may also lead to systemic inflammation and altered blood-brain barrier, leading to brain inflammation, a known pathophysiological event in Parkinson's disease.

[0351] Example 2 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for promoting the production of SCFAs by the gut microbiota by administering a liquid water-based probiotic composition. These methods are particularly effective in promoting intestinal health. The invention also relates to methods of promoting intestinal barrier integrity, methods of promoting tolerogenic intestinal phenotypes, and methods of treating Parkinson's disease.

Description

technical field [0001] The present invention relates to a method of promoting SCFA production by gut microbiota by administering a liquid water-based probiotic composition. These methods are particularly effective in promoting gut health. The present invention also relates to methods of promoting intestinal barrier integrity, methods of promoting tolerogenic intestinal phenotypes, and methods of treating Parkinson's disease. Background technique [0002] Short-chain fatty acids (SCFAs) play multiple important roles in the human gut microenvironment, including serving as a food source for host epithelial and mucosal cells and regulating local pH conditions. In addition, SCFAs serve as a food source for microbiota bacteria, where the complex interrelationships between SCFA production, metabolism, and cross-feeding contribute to the overall composition and health of the gut microbiota, and thus the gut itself. [0003] The production of SCFAs usually results from carbohydrate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L33/135A23L33/00A61K35/744A61K35/747A61P1/14
CPCA23L33/135A23L33/40A23V2002/00A61K35/744A61K35/747A61P25/16A61P1/16Y02A50/30A61K2300/00A23V2200/3204A23V2400/113A23V2400/169A23V2400/175
Inventor B·史密斯M·巴特勒
Owner MULTIGERM UK ENTERPRISES
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com